Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.3, and our video podcast, CANCER BUZZ TV.


The Evolving Landscape of Mantle Cell Lymphoma

Monday, June 21
12:00 PM CT

This case-based discussion provides an overview of mantle cell lymphoma (MCL), including its pathogenesis, diagnosis, risk assessment, and treatment. Topics covered include the use of CAR T-cell therapy and the most recently approved Bruton’s Tyrosine Kinase inhibitors, as well as treatment options and factors that affect clinical decision making in MCL.

Amitkumar Mehta, MD
Assistant Professor of Hematology and Oncology
University of Alabama at Birmingham


This is a promotional program sponsored by BeiGene.

Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer

Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence, and performance gaps exist in the optimal management of metastatic castration-sensitive prostate cancer (mCSPC).

This webinar addresses some of the challenges in optimal sequencing of care in mCSPC and strategies for translating new research into patient care strategies.

Presented by:

Pedro C. Barata, MD, MSC
Assistant Professor, Deming Department of Medicine Division of Hematology/Oncology, Genitourinary Cancers
Tulane University

Lisa M. Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor, UConn School of Pharmacy
Associate Professor, UConn School of Medicine


This activity was in collaboration with the Association of Community Cancer Centers (ACCC). 


Characterizing and Targeting a Tumor Immune Microenvironment in FGFR-Mutated Bladder Cancer

Novel immunotherapy drugs are used to treat advanced bladder cancer when chemotherapy is no longer working. However, only one in five patients responds to immunotherapy, likely due to biological differences in bladder cancer. Hear Dr. Andreev-Drakhlin—recipient of The ASCO Foundation 2020 Conquer Cancer Young Investigator Award— presents his research plans in using fibroblast growth factor receptor (FGFR) inhibitors for improving the effectiveness of immunotherapy for bladder cancer.

Presented by:
Alexander Andreev-Drakhlin, MD
Medical Oncology Fellow
University of Texas MD Anderson Cancer Center

ACCCeLearning-OSS - 500x135

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us